View in EDS

Nucleocapsid protein enhances spike- and RBD-specific humoral and cellular immune responses in protein-based SARS-CoV-2 vaccine.

Saved in:
Bibliographic Details
Title: Nucleocapsid protein enhances spike- and RBD-specific humoral and cellular immune responses in protein-based SARS-CoV-2 vaccine.
Authors: Gröhn S; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Lehto H; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Soppela S; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Naves RA; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Nordic SARS Response AB, Stockholm, Sweden., Ritvos MA; Nordic SARS Response AB, Stockholm, Sweden.; School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden., Iakubovskaia A; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Lampinen V; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Mustonen I; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Pakkala S; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Husu E; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Kakkola L; Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.; Clinical Microbiology, Turku University Hospital, Turku, Finland., Julkunen I; Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.; Clinical Microbiology, Turku University Hospital, Turku, Finland.; InFlames Research Flagship Center, University of Turku, Turku, Finland., Kolehmainen P; Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland., Pasternack A; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Nordic SARS Response AB, Stockholm, Sweden., Ritvos O; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Hankaniemi MM; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. minna.hankaniemi@tuni.fi.
Source: BMC infectious diseases [BMC Infect Dis] 2026 Jan 29; Vol. 26 (1). Date of Electronic Publication: 2026 Jan 29.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41612250
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Nucleocapsid protein enhances spike- and RBD-specific humoral and cellular immune responses in protein-based SARS-CoV-2 vaccine.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gröhn+S%22">Gröhn S</searchLink>; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.<br /><searchLink fieldCode="AU" term="%22Lehto+H%22">Lehto H</searchLink>; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.<br /><searchLink fieldCode="AU" term="%22Soppela+S%22">Soppela S</searchLink>; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.<br /><searchLink fieldCode="AU" term="%22Naves+RA%22">Naves RA</searchLink>; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Nordic SARS Response AB, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Ritvos+MA%22">Ritvos MA</searchLink>; Nordic SARS Response AB, Stockholm, Sweden.; School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Iakubovskaia+A%22">Iakubovskaia A</searchLink>; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Lampinen+V%22">Lampinen V</searchLink>; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.<br /><searchLink fieldCode="AU" term="%22Mustonen+I%22">Mustonen I</searchLink>; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.<br /><searchLink fieldCode="AU" term="%22Pakkala+S%22">Pakkala S</searchLink>; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.<br /><searchLink fieldCode="AU" term="%22Husu+E%22">Husu E</searchLink>; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.<br /><searchLink fieldCode="AU" term="%22Kakkola+L%22">Kakkola L</searchLink>; Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.; Clinical Microbiology, Turku University Hospital, Turku, Finland.<br /><searchLink fieldCode="AU" term="%22Julkunen+I%22">Julkunen I</searchLink>; Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.; Clinical Microbiology, Turku University Hospital, Turku, Finland.; InFlames Research Flagship Center, University of Turku, Turku, Finland.<br /><searchLink fieldCode="AU" term="%22Kolehmainen+P%22">Kolehmainen P</searchLink>; Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.<br /><searchLink fieldCode="AU" term="%22Pasternack+A%22">Pasternack A</searchLink>; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Nordic SARS Response AB, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Ritvos+O%22">Ritvos O</searchLink>; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Hankaniemi+MM%22">Hankaniemi MM</searchLink>; Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. minna.hankaniemi@tuni.fi.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100968551%22">BMC infectious diseases</searchLink> [BMC Infect Dis] 2026 Jan 29; Vol. 26 (1). <i>Date of Electronic Publication: </i>2026 Jan 29.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100968551 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1471-2334 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214712334%22">14712334 </searchLink><i>NLM ISO Abbreviation: </i>BMC Infect Dis <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41612250
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s12879-026-12634-x
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Nucleocapsid protein enhances spike- and RBD-specific humoral and cellular immune responses in protein-based SARS-CoV-2 vaccine.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gröhn S
      – PersonEntity:
          Name:
            NameFull: Lehto H
      – PersonEntity:
          Name:
            NameFull: Soppela S
      – PersonEntity:
          Name:
            NameFull: Naves RA
      – PersonEntity:
          Name:
            NameFull: Ritvos MA
      – PersonEntity:
          Name:
            NameFull: Iakubovskaia A
      – PersonEntity:
          Name:
            NameFull: Lampinen V
      – PersonEntity:
          Name:
            NameFull: Mustonen I
      – PersonEntity:
          Name:
            NameFull: Pakkala S
      – PersonEntity:
          Name:
            NameFull: Husu E
      – PersonEntity:
          Name:
            NameFull: Kakkola L
      – PersonEntity:
          Name:
            NameFull: Julkunen I
      – PersonEntity:
          Name:
            NameFull: Kolehmainen P
      – PersonEntity:
          Name:
            NameFull: Pasternack A
      – PersonEntity:
          Name:
            NameFull: Ritvos O
      – PersonEntity:
          Name:
            NameFull: Hankaniemi MM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 29
              M: 01
              Text: 2026 Jan 29
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1471-2334
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: BMC infectious diseases
              Type: main
ResultId 1